DCVC Bio

DCVC Bio is a dedicated vertical inside the $4B DCVC franchise, established in 2018 by Dr. John Hamer, Dr. Kiersten Stead, and DCVC co-founders Matthew Ocko and Zachary Bogue. It operates with its own three funds and investment team but shares back-office, operating partners, and the Data Collective brand. The parent runs six flagship funds focused on deep tech broadly, while DCVC Bio concentrates on computationally enabled life sciences.

Dr. John Hamer and Dr. Kiersten Stead are the Managing Partners specifically for DCVC Bio, per the firm's team page. They lead an investment group that includes Partner Dr. Justin Kern and Principal Dr. Emily Park. The broader DCVC franchise is led by Co-Founders Zachary Bogue and Matthew Ocko.

DCVC Bio makes direct venture investments from its three dedicated bio funds. The firm's website shows the broader DCVC franchise invests in companies from seed to growth stages, while the bio team applies that direct investing model to therapeutics, agriculture, and industrial biotechnology. The firm does not publicly discuss investing into other venture funds.

The portfolio spans therapeutics, agriculture, and industrial biotech. Confirmed positions include Latus Bio, which is developing precisely tuned viral vectors for CNS gene therapy, Pivot Bio, which reprograms soil microbes to provide nitrogen sustainably, and assets applying machine learning to disease biology. The firm's team draws on genetics, chemistry, molecular biology, and fermentation expertise to invest from preclinical through commercialization.

DCVC does not disclose a separate AUM for DCVC Bio. The parent franchise states it manages roughly $4 billion across 13 funds. No public filing or press report specifies the allocation to the three bio-specific funds.